PAC-1 is under clinical development by Vanquish Oncology and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect PAC-1’s likelihood of approval (LoA) and phase transition for Neuroendocrine Tumors took place on 16 Dec 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
In addition, the same event on 16 Dec 2022 increased PAC-1’s LoA and PTSR for Pancreatic Endocrine Tumor, and increased PTSR for Solid Tumor.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their PAC-1 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
PAC-1 (also known as VO-100) is under development for the treatment of anaplastic astrocytoma, glioblastoma multiforme (gbm), neuroendocrine tumors, lymphoma, pancreatic neuroendocrine tumor and solid tumors. The drug candidate is formulated as a capsule and administered orally and it acts by targeting a cellular enzyme, procaspase-3.
Vanquish Oncology overview
Vanquish Oncology is a biotechnology company which develops targeted, small-molecule oncology therapeutics for unmet or underserved cancer markets. The company is headquartered in Champaign, Illinois, the US.
Quick View PAC-1 LOA Data
|Highest Development Stage|